Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.

Mondy KE, Gottdiener J, Overton ET, Henry K, Bush T, Conley L, Hammer J, Carpenter CC, Kojic E, Patel P, Brooks JT; SUN Study Investigators.

Clin Infect Dis. 2011 Feb 1;52(3):378-86. doi: 10.1093/cid/ciq066. Epub 2010 Dec 9.

PMID:
21217185
2.

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F; Spanish Pneumococcal Infection Study Network (G03/103).

Arch Intern Med. 2005 Jul 11;165(13):1533-40.

PMID:
16009870
3.

Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection.

Plebani A, Esposito S, Pinzani R, Fesslova V, Bojanin J, Salice P, Rossi M, Principi N.

Pediatr Infect Dis J. 2004 Jun;23(6):559-63.

PMID:
15194840
4.

Cardiovascular disease and HIV infection: host, virus, or drugs?

Martínez E, Larrousse M, Gatell JM.

Curr Opin Infect Dis. 2009 Feb;22(1):28-34. doi: 10.1097/QCO.0b013e328320a849. Review.

PMID:
19532078
5.

The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.

Vilchez RA, Finch CJ, Jorgensen JL, Butel JS.

Medicine (Baltimore). 2003 Mar;82(2):77-81.

7.

Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.

Barbaro G.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):337-43.

PMID:
16101566
8.

Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London.

Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA.

J Oral Pathol Med. 2002 Mar;31(3):169-74.

PMID:
11903824
9.

Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy.

Guibert G, Warszawski J, Le Chenadec J, Blanche S, Benmebarek Y, Mandelbrot L, Tubiana R, Rouzioux C, Leruez-Ville M; French Perinatal Cohort.

Clin Infect Dis. 2009 Jun 1;48(11):1516-25. doi: 10.1086/598934.

PMID:
19388872
10.

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.

PMID:
15770006
11.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520
12.

Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy.

Floris-Moore M, Lo Y, Klein RS, Budner N, Gourevitch MN, Moskaleva G, Schoenbaum EE.

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):331-7.

PMID:
14600580
13.

Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy.

Domingo P, Suarez-Lozano I, Torres F, Pomar V, Ribera E, Galindo MJ, Cosin J, Garcia-Alcalde ML, Vidal F, Lopez-Aldeguer J, Roca B, Gonzalez J, Lozano F, Garrido M; VACH Cohort Study Group.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):582-7. doi: 10.1097/QAI.0b013e3181adcb01.

PMID:
19512939
14.

Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort.

Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, Ravasio V, Ripamonti D, Suter F, Maggiolo F.

Infection. 2011 Feb;39(1):13-20. doi: 10.1007/s15010-010-0079-z. Epub 2011 Jan 19.

PMID:
21246246
15.

The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.

Dorrucci M, Valdarchi C, Suligoi B, Zaccarelli M, Sinicco A, Giuliani M, Vlahov D, Pezzotti P, Rezza G.

AIDS. 2004 Nov 19;18(17):2313-8.

PMID:
15577544
16.

N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.

Berg T, Zdunek D, Stalke J, Dupke S, Baumgarten A, Carganico A, Hess G.

Eur J Med Res. 2007 Apr 26;12(4):152-60.

PMID:
17509959
17.

Metabolic syndrome in HIV-infected patients: no different than the general population?

Jones CY.

Clin Infect Dis. 2007 Mar 1;44(5):735-8. Epub 2007 Jan 22. No abstract available.

PMID:
17278069
18.

Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.

Bergersen BM, Sandvik L, Bruun JN, Tonstad S.

Eur J Clin Microbiol Infect Dis. 2004 Aug;23(8):625-30. Epub 2004 Jul 28.

PMID:
15322938
20.

Cardiovascular disease and toxicities related to HIV infection and its therapies.

Zareba KM, Miller TL, Lipshultz SE.

Expert Opin Drug Saf. 2005 Nov;4(6):1017-25. Review.

PMID:
16255661

Supplemental Content

Support Center